论文部分内容阅读
目的:探讨乳腺癌中免疫组化法(IHC)检测cerbB2蛋白表达和荧光原位杂交法(FISH)检测Her2基因扩增,并评估其临床意义。方法:IHC及FISH法分别检测50例乳腺癌组织中cerbB2蛋白表达及Her2基因扩增状态,并进行分析比较。结果:50例乳腺癌中Her2蛋白表达(++)者21例中,17例出现Her2基因扩增(80.95%),4例无扩增;Her2蛋白表达(+++)者29例中,28例出现Her2基因扩增(96.55%),1例无扩增;50例乳腺癌中共有45例Her2基因扩增(90%),5例无扩增。两种方法的检测结果阳性率差异无统计学意义(P>0.05)。结论:免疫组化检测Her2蛋白表达的情况可以做为临床治疗的初筛,免疫组化检测Her2蛋白表达(++)及(+++)的病例需要进一步行Her2基因的扩增,来确定临床治疗方案。
Objective: To investigate the detection of cerbB2 protein by immunohistochemistry (IHC) in breast cancer and the detection of Her2 gene amplification by fluorescence in situ hybridization (FISH) and to evaluate its clinical significance. Methods: The expressions of cerbB2 protein and Her2 gene in 50 cases of breast cancer were detected by IHC and FISH, respectively. Results: Her2 gene amplification (80.95%) occurred in 17 out of 21 cases of Her2 protein expression (++) in 50 cases of breast cancer without amplification; in 29 cases of Her2 protein expression (+++) Her2 gene amplification (96.55%) occurred in 28 cases, no amplification in 1 case; 45 cases of Her2 gene amplification (90%) in 50 cases of breast cancer without amplification in 5 cases. There was no significant difference between the two methods (P> 0.05). Conclusion: The immunohistochemical detection of Her2 protein expression can be used as a preliminary screening of clinical treatment, immunohistochemistry Her2 protein expression (++) and (+++) cases need to further Her2 gene amplification to determine Clinical treatment plan.